Cellectis (CLLS) Other Non Operating Income (2021 - 2025)
Cellectis (CLLS) posted quarterly Other Non Operating Income of $1.1 billion for Q3 2025, up 112.14% year-over-year from $540.2 million in Q3 2024, and up 399203.14% quarter-over-quarter from $287000.0 in Q2 2025.
Powered by 
Analysis
Cellectis (CLLS) Other Non Operating Income (2021 - 2025) Analysis & Trends
Cellectis' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $1.1 billion for Q3 2025.
- In Q3 2025, Other Non Operating Income rose 112.14% year-over-year to $1.1 billion; the TTM figure through Sep 2025 stood at -$8.3 billion (up 12.15% YoY), while the FY2021 annual figure was $1.5 million, changed N/A from the prior year.
- Other Non Operating Income for Q3 2025 stood at $1.1 billion, up from $287000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $1.1 billion in Q3 2025, with the low at -$9.4 billion in Q3 2024.
- The 5-year median for Other Non Operating Income is $118000.0 (2021), against an average of -$518.2 million.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income plunged 5826643.21% in 2024, then soared 856.67% in 2025.
- Cellectis' Other Non Operating Income stood at $3.5 million in 2021, then sank by 353.16% to -$8.9 million in 2022, then soared by 101.82% to $162000.0 in 2023, then slumped by 5826643.21% to -$9.4 billion in 2024, then surged by 112.14% to $1.1 billion in 2025.
- Business Quant data shows CLLS's Other Non Operating Income at $1.1 billion in Q3 2025, $287000.0 in Q2 2025, and $750000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Cellectis | 325.91 Mn | 159.06 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -415,000.00 |
| Sep 30, 2025 | -283,000.00 |
| Jun 30, 2025 | 287,000.00 |
| Mar 31, 2025 | 750,000.00 |
| Dec 31, 2024 | -562,000.00 |
| Sep 30, 2024 | 370,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | -146,000.00 |
| Dec 31, 2023 | -169,000.00 |
| Sep 30, 2023 | 162,000.00 |
| Jun 30, 2023 | 95,000.00 |
| Mar 31, 2023 | -80,000.00 |
| Dec 31, 2022 | -73,000.00 |
| Sep 30, 2022 | -210,000.00 |
| Jun 30, 2022 | -255,000.00 |
| Mar 31, 2022 | -126,000.00 |
| Dec 31, 2021 | 2.71 Mn |
| Sep 30, 2021 | 12.92 Mn |
| Jun 30, 2021 | -15.05 Mn |
| Mar 31, 2021 | 141,000.00 |